(12) Patent Application Publication (10) Pub. No.: US 2007/0077288A1 Klose Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) Patent Application Publication (10) Pub. No.: US 2007/0077288A1 Klose Et Al US 20070077288A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0077288A1 Klose et al. (43) Pub. Date: Apr. 5, 2007 (54) TRANSDERMAL DELIVERY OF now Pat. No. 6,299,900, filed as 371 of international NON-STEROIDAL ANTI-NFLAMMATORY application No. PCT/AU97/00091, filed on Feb. 19, DRUGS 1997. (75) Inventors: Kathryn Traci-Jane Klose, Bonbeach (30) Foreign Application Priority Data (AU); Margarita Vladislavova Bakalova, Bundoora (AU); Timothy Feb. 19, 1996 (AU)........................................ PN8144796 Matthias Morgan, Carlton North (AU); Berrie Charles Finnin, Glen Iris (AU); Publication Classification Barry Leonard Reed, Strathmore (AU) (51) Int. Cl. Correspondence Address: A6IR 8/37 (2006.01) FOLEY AND LARDNER LLP A6IR 8/49 (2006.01) SUTE SOO A6II 3 L/60 (2006.01) 3OOOK STREET NW (52) U.S. Cl. ............................. 424/449; 514/159: 424/59 WASHINGTON, DC 20007 (US) (57) ABSTRACT (73) Assignee: Acrux DDS Pty Ltd. The present invention provides a transdermal drug delivery (21) Appl. No.: 11/517,575 system which comprises: a therapeutically effective amount (22) Filed: Sep. 8, 2006 of a non-steroidal anti-inflammatory drug; at least one dermal penetration enhancer, which is a safe skin-tolerant Related U.S. Application Data ester Sunscreen ester, and at least one volatile liquid. The invention also provides a method for administering at least (60) Continuation-in-part of application No. 10/759,303, one systemic or locally acting non-steroidal anti-inflamma filed on Jan. 20, 2004, which is a continuation-in-part tory drug to an animal which comprises applying an effec of application No. 09/910,780, filed on Jul. 24, 2001, tive amount of the non-steroidal anti-inflammatory drug in now Pat. No. 6,818,226, which is a division of the form of the drug delivery system of the present inven application No. 09/125,436, filed on Dec. 18, 1998, tion. -O- 5% whw ibuprofen, 5% wiv Padimate On=3 8 -O- 5% w/w ibuprofen n=3 O C4 O 0 1 2 3 4 5 6 7 8 g 101112131415 1617 18192021222324 Time (hours) Patent Application Publication Apr. 5, 2007 Sheet 1 of 2 US 2007/0077288A1 9 -O- 5% w/w Ibuprofen, 5% w/w Padimate On=3 -O- 5% whv ibuprofen n=3 0 1 2 3 4 5 6 7 8 9 10 1112131415 161718 192021222324 Time (hours) FIGURE 1 Patent Application Publication Apr. 5, 2007 Sheet 2 of 2 US 2007/0077288A1 ld O S. S g g S N LD CN O n ON s U C2 O CN co 2 aC. sC. ses o A. C. s e-M E 2 S. o 5 ae is Sn Fmam - C - 9 S &SS 2 s 5 CO SS e --Sn O 33a iSSS w O ld Co Lo o ld O O ld O on O N. L CN O N Ld on CN CN v vm v wn (u06)N3OldNSOLNNOWV3NIVANNO FIGURE 2 US 2007/0077288 A1 Apr. 5, 2007 TRANSIDERMAL DELVERY OF NON-STEROIDAL partitioned from the stratum corneum to the viable epidermis ANTI-NFLAMMATORY DRUGS and then into the dermal circulation. 0001. This application is a continuation-in-part of U.S. 0007 To overcome some of the problems with transder patent application Ser. No. 10/759,303 filed Jan. 20, 2004, mal delivery that are associated with transport across the which is a continuation-in-part of U.S. Pat. No. 6,818,226, dermal layers (percutaneous absorption), physiologically filed Jul. 24, 2001, which is a divisional of U.S. Pat. No. active agents are commonly formulated with incorporation 6,299,900, filed Dec. 18, 1998 as the U.S. national stage of one or more dermal penetration enhancers (Finnin and application of PCT application PCT/AU97/00091, filed Feb. Morgan, J. Pharm. Sci., Vol 88, No. 10, October 1999, pp. 19, 1997. The entire contents of each of U.S. patent appli 955-958) which are often lipophilic chemicals that readily cation Ser. No. 10/759,303, U.S. Pat. No. 6,818,226, U.S. partition into the stratum corneum whereupon they exert Pat. No. 6,299,900, and PCT application PCT/AU97/00091 their effects on improving the transport of drugs across the are incorporated herein by reference, and priority to each is skin barrier. claimed under 35 U.S.C. S 119 and/or S120. 0008. There is a need for improvements in the transder mal delivery of non-steroidal anti-inflammatory drugs. FIELD OF THE INVENTION 0002 The present invention relates to transdermal drug SUMMARY OF THE INVENTION delivery. More specifically, the invention relates to a topical 0009. According to the present invention there is pro absorption/penetration enhancing agent for use in the deliv vided a transdermal drug delivery system comprising: ery of non-steroidal anti-inflammatory drugs and non-ste roidal anti-inflammatory drug derivatives to an animal, 0010 (a) a therapeutically effective amount of a non including a human. The invention also relates to a system for steroidal anti-inflammatory drug; the non-occlusive delivery to an animal of non-steroidal 0011 (b) at least one dermal penetration enhancer, anti-inflammatory drugs and non-steroidal anti-inflamma which is a safe skin-tolerant ester Sunscreen of formula tory drug derivatives across a dermal Surface of the animal. (I): Transdermal drug formulations of the present invention may be used for local application or systemic delivery. (I) BACKGROUND OF THE INVENTION N (CH=CH)-COR2 0003. There is a constant need for methods for the safe (R)- and effective administration of physiologically active 21 agents, such as non-steroidal anti-inflammatory drugs. For many medications it is important that the administration regime is as simple and non-invasive as possible in order to 0012 wherein maintain a high level of compliance by a patient. Oral 0013) R' is hydrogen, lower alkyl, lower alkoxy, administration is one administration regime that is com halide, hydroxy or NR R: monly used because it is a relatively simple regime to follow. However, the oral administration route is also com 0014) R is a Cls to Cls alkyl: plicated because of complications associated with gas 0015 R and R are each independently hydrogen, trointestinal irritation and with drug metabolism in the liver. lower alkyl or R and R together with the nitrogen 0004 Administration of physiologically active agents atom to which they are attached form a 5- or 6-mem through the skin (transdermal drug delivery) has received bered heterocyclic ring; increased attention because it not only provides a relatively simple dosage regime but it also provides a relatively slow 0016 n is 0 or 1, and and controlled route for release of a physiologically active 0017 q is 1 or 2, agent into the systemic circulation. However, transdermal 0018 wherein, when n is 0 and R' is NR'R'', then NR drug delivery is complicated by the fact that the skin behaves R" is para-substituted, and wherein said dermal pen as a natural barrier and therefore transport of agents through etration enhancer is present in an amount of from about the skin is a complex mechanism. 10 to about 10,000 wt % based on the weight of the 0005 Structurally, the skin consists of two principle non-steroidal anti-inflammatory drug; and parts, a relatively thin outermost layer (the epidermis) and a thicker inner region (the dermis). The outermost layer of 0019 (c) at least one volatile liquid. the epidermis (the stratum corneum) consists of flattened 0020. In addition to providing improved percutaneous dead cells which are filled with keratin. The region between absorption efficiency, the composition of the invention may the flattened dead cells of the stratum corneumare filled with also provide lower irritancy than Some other more occlusive lipids which form lamellar phases that are responsible for delivery systems such as transdermal patches, because the the natural barrier properties of the skin. composition is non-occlusive to the skin. 0006 For effective transdermal delivery of a physiologi 0021 More preferably the dermal penetration enhancer is cally active agent that is applied to the Surface of the skin selected from the group consisting of a Cs to Cs alkyl (topical application), the agent must be partitioned firstly para-aminobenzoate, Cs to Cs alkyl dimethyl-para-ami from the vehicle into the stratum corneum, it must typically nobenzoate, Cs to Cs alkyl cinnamate, Cs to Cs alkyl then be diffused within the stratum corneum before being methoxycinnamate or Cs to Cs alkyl salicylate. Most pref US 2007/0077288 A1 Apr. 5, 2007 erably the dermal penetration enhancer is octyl salicylate from about 1 to 10% of the at least one dermal penetration (2-ethylhexyl salicylate, octisalate), octyl dimethyl para enhancer and from about 75 to 98% ethanol, isopropanol or aminobenzoate or octyl para-methoxycinnamate (Padimate mixture thereof. O). 0026. In another preferred form of the invention the drug 0022. The drug delivery systems according to the inven delivery system comprises, on a weight basis, from about 1 to 5% of an non-steroidal anti-inflammatory drug, from tion may comprise one or more non-steroidal anti-inflam about 1 to 5% of at least one dermal penetration enhancer, matory drugs together with the penetration enhancer incor which is a safe skin-tolerant ester Sunscreen, from about 45 porated into a dosage form for topical application to the skin to 90% ethanol, isopropanol or mixture thereof, 5 to 45% of animals. Suitable dosage forms include creams, lotions, water; and optionally 0.5 to 5% of a thickening agent. gels, ointments, mousses, sprays, aerosols, or any one of a variety of transdermal devices for use in the continuous 0027.
Recommended publications
  • United States Patent (19) 11 Patent Number: 5,955,504 Wechter Et Al
    USOO5955504A United States Patent (19) 11 Patent Number: 5,955,504 Wechter et al. (45) Date of Patent: Sep. 21, 1999 54 COLORECTAL CHEMOPROTECTIVE Marnett, “Aspirin and the Potential Role of Prostaglandins COMPOSITION AND METHOD OF in Colon Cancer, Cancer Research, 1992; 52:5575–89. PREVENTING COLORECTAL CANCER Welberg et al., “Proliferation Rate of Colonic Mucosa in Normal Subjects and Patients with Colonic Neoplasms: A 75 Inventors: William J. Wechter; John D. Refined Immunohistochemical Method.” J. Clin Pathol, McCracken, both of Redlands, Calif. 1990; 43:453-456. Thun et al., “Aspirin Use and Reduced Risk of Fatal Colon 73 Assignee: Loma Linda University Medical Cancer." N Engl J Med 1991; 325:1593-6. Center, Loma Linda, Calif. Peleg, et al., “Aspirin and Nonsteroidal Anti-inflammatory Drug Use and the Risk of Subsequent Colorectal Cancer.” 21 Appl. No.: 08/402,797 Arch Intern Med. 1994, 154:394–399. 22 Filed: Mar 13, 1995 Gridley, et al., “Incidence of Cancer among Patients With Rheumatoid Arthritis J. Natl Cancer Inst 1993 85:307-311. 51) Int. Cl. .......................... A61K 31/19; A61K 31/40; Labayle, et al., “Sulindac Causes Regression Of Rectal A61K 31/42 Polyps. In Familial Adenomatous Polyposis” Gastroenterol 52 U.S. Cl. .......................... 514/568; 514/569; 514/428; ogy 1991 101:635-639. 514/416; 514/375 Rigau, et al., “Effects Of Long-Term Sulindac Therapy On 58 Field of Search ..................................... 514/568, 570, Colonic Polyposis” Annals of Internal Medicine 1991 514/569, 428, 416, 375 11.5:952-954. Giardiello.et al., “Treatment Of Colonic and Rectal 56) References Cited Adenomas With Sulindac In Familial Adenomatous Poly U.S.
    [Show full text]
  • Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm
    Table S1: Sensitivity, specificity, PPV, NPV, and F1 score of NLP vs. ICD for identification of symptoms for (A) BioMe development cohort; (B) BioMe validation cohort; (C) MIMIC-III; (D) 1 year of notes from patients in BioMe calculated using manual chart review. A) Fatigue Nausea and/or vomiting Anxiety Depression NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.99 (0.93- 0.59 (0.43- <0.00 0.25 (0.12- <0.00 <0.00 0.54 (0.33- Sensitivity 0.99 (0.9 – 1) 0.98 (0.88 -1) 0.3 (0.15-0.5) 0.85 (0.65-96) 0.02 1) 0.73) 1 0.42) 1 1 0.73) 0.57 (0.29- 0.9 (0.68- Specificity 0.89 (0.4-1) 0.75 (0.19-1) 0.68 0.97 (0.77-1) 0.03 0.98 (0.83-1) 0.22 0.81 (0.53-0.9) 0.96 (0.79-1) 0.06 0.82) 0.99) 0.99 (0.92- 0.86 (0.71- 0.94 (0.79- 0.79 (0.59- PPV 0.96 (0.82-1) 0.3 0.95 (0.66-1) 0.02 0.95 (0.66-1) 0.16 0.93 (0.68-1) 0.12 1) 0.95) 0.99) 0.92) 0.13 (0.03- <0.00 0.49 (0.33- <0.00 0.66 (0.48- NPV 0.89 (0.4-1) 0.007 0.94 (0.63-1) 0.34 (0.2-0.51) 0.97 (0.81-1) 0.86 (0.6-0.95) 0.04 0.35) 1 0.65) 1 0.81) <0.00 <0.00 <0.00 F1 Score 0.99 0.83 0.88 0.57 0.95 0.63 0.82 0.79 0.002 1 1 1 Itching Cramp Pain NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.98 (0.86- 0.24 (0.09- <0.00 0.09 (0.01- <0.00 0.52 (0.37- <0.00 Sensitivity 0.98 (0.85-1) 0.99 (0.93-1) 1) 0.45) 1 0.29) 1 0.66) 1 0.89 (0.72- 0.5 (0.37- Specificity 0.96 (0.8-1) 0.98 (0.86-1) 0.68 0.98 (0.88-1) 0.18 0.5 (0-1) 1 0.98) 0.66) 0.88 (0.69- PPV 0.96 (0.8-1) 0.8 (0.54-1) 0.32 0.8 (0.16-1) 0.22 0.99 (0.93-1) 0.98 (0.87-1) NA* 0.97) 0.98 (0.85- 0.57 (0.41- <0.00 0.58 (0.43- <0.00 NPV 0.98 (0.86-1) 0.5 (0-1) 0.02 (0-0.08) NA* 1) 0.72) 1 0.72) 1 <0.00 <0.00 <0.00 F1 Score 0.97 0.56 0.91 0.28 0.99 0.68 1 1 1 *Denotes 95% confidence intervals and P values that could not be calculated due to insufficient cells in 2x2 tables.
    [Show full text]
  • What Are the Acute Treatments for Migraine and How Are They Used?
    2. Acute Treatment CQ II-2-1 What are the acute treatments for migraine and how are they used? Recommendation The mainstay of acute treatment for migraine is pharmacotherapy. The drugs used include (1) acetaminophen, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans and (5) antiemetics. Stratified treatment according to the severity of migraine is recommended: use NSAIDs such as aspirin and naproxen for mild to moderate headache, and use triptans for moderate to severe headache, or even mild to moderate headache when NSAIDs were ineffective in the past. It is necessary to give guidance and cautions to patients having acute attacks, and explain the methods of using medications (timing, dose, frequency of use) and medication use during pregnancy and breast-feeding. Grade A Background and Objective The objective of acute treatment is to resolve the migraine attack completely and rapidly and restore the patient’s normal functions. An ideal treatment should have the following characteristics: (1) resolves pain and associated symptoms rapidly; (2) is consistently effective; (3) no recurrence; (4) no need for additional use of medication; (5) no adverse effects; (6) can be administered by the patients themselves; and (7) low cost. Literature was searched to identify acute treatments that satisfy the above conditions. Comments and Evidence The acute treatment drugs for migraine generally include (1) acetaminophens, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans, and (5) antiemetics. For severe migraines including status migrainosus and migraine attacks refractory to treatment, (6) anesthetics, and (7) corticosteroids (dexamethasone) are used (Tables 1 and 2).1)-9) There are two approaches to the selection and sequencing of these medications: “step care” and “stratified care”.
    [Show full text]
  • Drug–Drug Salt Forms of Ciprofloxacin with Diflunisal and Indoprofen
    CrystEngComm View Article Online COMMUNICATION View Journal | View Issue Drug–drug salt forms of ciprofloxacin with diflunisal and indoprofen† Cite this: CrystEngComm,2014,16, 7393 Partha Pratim Bag, Soumyajit Ghosh, Hamza Khan, Ramesh Devarapalli * Received 27th March 2014, and C. Malla Reddy Accepted 12th June 2014 DOI: 10.1039/c4ce00631c www.rsc.org/crystengcomm Two salt forms of a fluoroquinolone antibacterial drug, Crystal engineering approach has been effectively ciprofloxacin (CIP), with non-steroidal anti-inflammatory drugs, utilized in recent times in the synthesis of new forms particu- diflunisal (CIP/DIF) and indoprofen (CIP/INDP/H2O), were synthe- larly by exploiting supramolecular synthons. Hence the sized and characterized by PXRD, FTIR, DSC, TGA and HSM. Crystal identification of synthons that can be transferred across Creative Commons Attribution-NonCommercial 3.0 Unported Licence. structure determination allowed us to study the drug–drug different systems is important. For example, synthon trans- interactions and the piperazine-based synthon (protonated ferability in cytosine and lamivudine salts was recently dem- piperazinecarboxylate) in the two forms, which is potentially useful onstrated by Desiraju and co-workers by IR spectroscopy for the crystal engineering of new salt forms of many piperazine- studies.20a Aakeröy and co-workers successfully estab- based drugs. lished the role of synthon transferability (intermolecular amide⋯amide synthons) in the assembly and organization of Multicomponent pharmaceutical forms consisting of an bidentate acetylacetonate (acac) and acetate “paddlewheel” active pharmaceutical ingredient (API) and an inactive 20b complexes of a variety of metal(II)ions. Recently Das et al. co-former,whichisideallyagenerally recognized as safe – have reported the gelation behaviour in various diprimary This article is licensed under a 1 3 (GRAS) substance, have been well explored in recent times.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Analgesic and Anti-Inflammatory Compositions Comprising of Using Same
    Europaisches Patentamt J) European Patent Office Publication number: 0 1 65 308 Office europeen des brevets B1 EUROPEAN PATENT SPECIFICATION Date of publication of patent specification: 22.03.89 Intel.4: A 61 K 31/19, A 61 K 31/53 Application number: 85900409.5 Date of filing: 12.12.84 International application number: PCT/US84/02035 International publication number: WO 85/02540 20.06.85 Gazette 85/14 XANTHINES AND METHODS ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING OF USING SAME. (30) Priority: 12.12.83 US 560576 Proprietor: Richardson-Vicks, Inc. Ten Westport Road Wilton, CT 06897 (US) (43) Date of publication of application: 27.12.85 Bulletin 85/52 Inventor: SUNSHINE, Abraham 254 East 68 Street Apt. 12D Publication of the grant of the patent: New York, NY 10021 (US) 22.03.89 Bulletin 89/12 Inventor: LASKA, Eugene, M. 34 Dante Street Larchmont, NY 10538 (US) Designated Contracting States: Inventor: SIEGEL, Carole, E. BEFR 1304 Colonial Court Mamaroneck, NY 10543 (US) References cited: WO-A-84/00487 @ Representative: Pendlebury, Anthony et al WO-A-84/00488 Page, White & Farrer 5 Plough Place New Fetter US-A-3439 094 Lane US-A-4479 956 London EC4A1HY(GB) Chemical Abstracts, vol. 96, no. 18, 3 May 1982, (58) References cited: Columbus, OH (US); Kaken Chemical Co.: 00 Clinical Pharmacol. Therapeutics, vol. 24, no. 1, "Combined analgesic and antipyretic A.K. et o 149 162u July 1978 (The C.V. Mosby Co.), Jain, formulations", p. 422, no. al.: and in « "Aspirin aspirin-caffeine postpartum pain relief, pp. 69-75 in Note: Within nine months from the publication of the mention of the grant of the European patent, any person may notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Indoprofen and Naproxen in the Treatment of Rheumatoid Arthritis
    274 BRITISH MEDICAL JOURNAL 4 FEBRUARY 1978 Discussion haemorrhagic side effects has been based on trials in which anticoagulant dosage was determined by extrinsic clotting testsBr Med J: first published as 10.1136/bmj.1.6108.274 on 4 February 1978. Downloaded from The British comparative thromboplastin or its routine alone-that is, Quick prothrombin time test or Thrombotest. counterpart the Manchester comparative reagent is used in Our results also show the interesting and important finding that almost all hospitals in Britain. The BCT is also used throughout surgery is safe when intrinsic clotting is depressed, as judged by the world as a reference material. Hitherto the lower limits of a prolongation of PTT, provided that this is not excessive. the therapeutic range have been defined by clinical experience For moderate-risk patients, the necessary preoperative and correlation with other monitoring systems used in Britain stabilisation period for oral anticoagulants makes this type of and overseas. Our study allows an objective evaluation of the prophylaxis unnecessarily troublesome. For these patients the effectiveness of oral anticoagulant dosage monitored by the present study endorses the effectiveness of the fixed low-dose BCT to be made. The DVT incidence in untreated patients heparin regimen. If, however, a patient is already stabilised on (23%) agrees with other series. It is similar to that in the study of oral anticoagulants, it is apparently not worth changing to low- Ballard et a14 in gynaecological patients (290') and to that in the dose heparin for the operative period, as has recently been multicentre trial study8 of mixed surgical patients (24°0).
    [Show full text]
  • (19) 11 Patent Number: 6165500
    USOO6165500A United States Patent (19) 11 Patent Number: 6,165,500 Cevc (45) Date of Patent: *Dec. 26, 2000 54 PREPARATION FOR THE APPLICATION OF WO 88/07362 10/1988 WIPO. AGENTS IN MINI-DROPLETS OTHER PUBLICATIONS 75 Inventor: Gregor Cevc, Heimstetten, Germany V.M. Knepp et al., “Controlled Drug Release from a Novel Liposomal Delivery System. II. Transdermal Delivery Char 73 Assignee: Idea AG, Munich, Germany acteristics” on Journal of Controlled Release 12(1990) Mar., No. 1, Amsterdam, NL, pp. 25–30. (Exhibit A). * Notice: This patent issued on a continued pros- C.E. Price, “A Review of the Factors Influencing the Pen ecution application filed under 37 CFR etration of Pesticides Through Plant Leaves” on I.C.I. Ltd., 1.53(d), and is subject to the twenty year Plant Protection Division, Jealott's Hill Research Station, patent term provisions of 35 U.S.C. Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252. 154(a)(2). (Exhibit B). K. Karzel and R.K. Liedtke, “Mechanismen Transkutaner This patent is Subject to a terminal dis- Resorption” on Grandlagen/Basics, pp. 1487–1491. (Exhibit claimer. C). Michael Mezei, “Liposomes as a Skin Drug Delivery Sys 21 Appl. No.: 07/844,664 tem” 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp 345-358. (Exhibit E). 22 Filed: Apr. 8, 1992 Adrienn Gesztes and Michael Mazei, “Topical Anesthesia of 30 Foreign Application Priority Data the Skin by Liposome-Encapsulated Tetracaine” on Anesth Analg 1988; 67: pp 1079–81. (Exhibit F). Aug. 24, 1990 DE) Germany ............................... 40 26834 Harish M. Patel, "Liposomes as a Controlled-Release Sys Aug.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,472,433 B2 Wechter (45) Date of Patent: Oct
    USOO6472433B2 (12) United States Patent (10) Patent No.: US 6,472,433 B2 Wechter (45) Date of Patent: Oct. 29, 2002 (54) METHOD FOR TREATMENT OF Variability of Inversion of (R)-Flurbiprofen in Different NFLAMMATION WITH R-NSAIDS Species, Sabine Menzel-Soglowek, Gerd Geisslinger, Win fried S. Beck, and Kay Brune-Journal of Pharmaceutical (75) Inventor: William J. Wechter, Ojai, CA (US) Sciences vol. 81, No. 9, Sep. 1992. Disposition and Pharmacokinetics of R-flurbiprofen in (73) Assignee: Loma Linda University Medical Three Species: Demonstration of R- to S-Flurbiprofen Center, Loma Linda, CA (US) Inversion in the Mouse, Rat and Monkey-William J. Wechter, E. David Murray, Jr. Karina M. Gibson, David D. (*) Notice: Subject to any disclaimer, the term of this Quiggle, and Douglas L. Leipold-Laboratory of Chemical patent is extended or adjusted under 35 Endocrinology, Loma Linda University School of Medicine, U.S.C. 154(b) by 0 days. 1998. Superaspirin, Jerome Groopman The New Yorker, Jun. 15, (21) Appl. No.: 09/797,022 1998 pp. 32–35. (22) Filed: Mar. 1, 2001 Building a Better Aspirin, Science, vol. 280, May 22, 1998. (65) Prior Publication Data R-Flurbiprofen Chemoprevention and Treatment of Intesti nal Adenomas in the APC Min/+ Mouse Model: Implica US 2001/0012849 A1 Aug. 9, 2001 tions for Prophylazis and Treatment of Colon Caner, Will iam Wechter, Darko Kantoci, E. David Murray, Jr. David D. Related U.S. Application Data Quiggle, Douglas D. Leipold, Karina M. Gibson, and John D. McCracker-Cancer Research 57, 4316-4324, Oct. 1, (63) Continuation of application No.
    [Show full text]